Synthesis and antibacterial activity of various substituted oxadiazole derivatives

Article abstract of DOI:10.1002/ardp.201000141

Some new 2-(2-(4(4-substitutedbenzoyl-2-methylphenoxy)acetyl)-N-(2- substitutedphenyl) hydrazinecarbothioamides (4a-4j) and (4-((5-(2- substitutedphenylamino)-1,3,4-oxadiazol-2-yl)methoxy)-3-substitutedphenyl) (phenyl)methanones (5a-5j) have been synthesi

Full text of DOI:10.1002/ardp.201000141

466
Arch. Pharm. Chem. Life Sci. 2011, 344, 466–473
Full Paper
Synthesis and Antibacterial Activity of Various Substituted
Oxadiazole Derivatives
Hemlata Kaur1, Sunil Kumar1, R. S. Verma2, Amit Garg3, K. K. Saxena1, Suman Lata1, and
Ashok Kumar1
1 Medicinal Chemistry Division, Department of Pharmacology, L.L.R.M. Medical College, Meerut, (U.P.)
India
2 Medicinal Chemistry Division, Department of Pharmacy, L.L.R.M. MedicalCollege, Meerut, (U.P.) India
3 Medicinal Chemistry Division, Department of Microbiology, L.L.R.M. Medical College, Meerut, (U.P.)
India
Some new 2-(2-(4(4-substitutedbenzoyl-2-methylphenoxy)acetyl)-N-(2-substitutedphenyl) hydrazinecarbo-
thioamides (4a–4j) and (4-((5-(2-substitutedphenylamino)-1,3,4-oxadiazol-2-yl)methoxy)-3-substituted-
phenyl)(phenyl)methanones (5a–5j) have been synthesized from 2-(4-(3-substitutedbenzoyl)-2-
methylphenoxy)acetohydrazides (3a, 3b). These newly synthesized compounds (4a–4j and 5a–5j)
were characterized by elemental and spectral (IR, 1H-NMR and MS) analysis. All the synthesized
compounds have been screened for their antibacterial activity against both types of Gram negative
and Gram positive bacteria. The most potent antibacterial compound of this series was compound 5i
which has the low MIC 3.75–0.9375 mg/mL value. Both minimal inhibitory concentration (MIC) and
inhibition zones were determined in order to monitor the efficacy of the synthesized compounds.
Certain compounds inhibit bacterial growth with low MIC (mg/mL) value.
Keywords: Antibacterial activity / Oxadiazole / Toxicity study
Received: May 18, 2010; Revised: September 15, 2010; Accepted: September 17, 2010
DOI 10.1002/ardp.201000141
Introduction
methanone (5a–5h) with the hope to get better antibacterial
agents.
Five membered nitrogen containing heterocycles with oxy-
gen atom are an important class of compounds in medicinal Chemistry
chemistry. Oxadiazole derivatives have attracted much atten-
tion among five-membered oxygen containing heterocycles
because of their biological and pharmacological properties
like antibacterial [1–3], antimicrobial [4, 5], fungicidal [6],
anti-inflammatory [7], antipsychotic [8], anticonvulsant [8],
and antidepressant [9]. In the light of above discussion we
report herein the synthesis of 2-(2-(4-benzoyl-2-methyl-
phenoxy)acetyl)-N-(2-substitutedethoxyphenyl)hydrazinecarbo-
thioamides (4a–4h) and (4-((5-(2-substitutedphenylamino)-
1,3,4-oxadiazol-2-yl)methoxy)-3-methylphenyl)(phenyl)-
The synthetic route of the title compounds is outlined in
Scheme 1. The starting compounds 2-(4-(3-substitutedben-
zoyl)-2-methylphenoxy) acetates (2a, 2b) were prepared by
the reaction of substituted 4-hydroxybenzophenones (1a,
1b) with ethyl bromoacetate. Compounds 2a, 2b on treat-
ment with hydrazine hydrate yielded 2-(4-(3-substitutedben-
zoyl)-2-methylphenoxy) acetohydrazides (3a, 3b). Further, the
compounds 3a, 3b were converted into 2-(2-(4-(3-sustituted-
benzoyl)-2-methylphenoxy)acetyl)-N-(2-substitutedphenyl)hy-
drazinecarbothioamides (4a–4j), on reaction with various
substituted phenylisothiocynates. Compounds 4a–4j reacted
with sodium hydroxide and potassium iodide to obtain
(3-substitutedphenyl)-(3-methyl-4-((5-(2-substitutedphenyl-
amino)-1,3,4-oxadiazol-2-yl)methoxy)phenyl)methanones (5a–
5j). Structural assignments of the above newly synthesized
Correspondence: Ashok Kumar, Medicinal Chemistry Division,
Department of Pharmacology, L.L.R.M. Medical College, Meerut 250004,
(U.P.) India.
E-mail: kshokraj@gmail.com
Fax: þ91 121 2760888
ß 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

Arch. Pharm. Chem. Life Sci. 2011, 344, 466–473
Synthesis of New Oxadiazole Derivatives
467
O
CH
3
OH
O
inhibitory concentration (MIC) in mg/mL of all the com-
pounds were given in Tables 1 and 2. Dimethyl sulfoxide
treated group served as a control. The compounds 4a–4j
exhibited varying antibacterial response against different
types of bacterial strains, but the compounds having electro-
negative groups such as Br and Cl, showed better results than
the other compounds. The compounds 4e, 4f and 4j (having
ethylphenyl, methylphenyl, and ethylphenyl moieties,
respectively) were devoid of antibacterial activity against
Gram negative bacteria P. aeruginosa ATCC 27853 and
K. pneumoniae CIP 53153. These compounds showed mild
antibacterial activity against E. coli ATCC 25922 with MIC
120, 250, and 120 mg/mL, respectively. The compounds 4e
and 4f exhibited moderate activity against Gram positive
bacteria S. aureus ATCC 25923 with MIC 60 and 90 mg/mL,
respectively. Among the compounds 4a–4j, compound 4i
having chlorophenyl ring exhibited good antibacterial
activity against Gram negative bacteria P. aeruginosa ATCC
27853 and E. coli ATCC 25922 and Gram positive bacteria
S. aureus ATCC 25923 with MIC 15 mg/mL for each.
Moreover, compound 4h having bromophenyl ring showed
good activity against Gram negative bacteria E. coli ATCC
25922 with MIC 15 mg/mL and moderate antibacterial
activity against K. pneumoniae CIP 53153 with MIC 30 mg/mL.
Formation of the compounds 5a-5j (having oxadiazole ring)
markedly enhanced the antibacterial activity against both
types of bacteria. Out of these compounds, 5f, 5g, 5h and 5j
exhibited significant antibacterial activity against different
types of bacterial strains. Furthermore, the compound 5i
(having chlorophenyl ring) has shown most potent antibac-
terial activity against Gram negative bacteria P. aeruginosa
ATCC 27853 (MIC 3.75 mg/mL), K. pneumoniae CIP 53153 (MIC
1.875 mg/mL), E. coli ATCC 25922 (MIC 3.75 mg/mL). The later
compound exhibited maximum antibacterial activity against
Gram positive bacteria S. aureus ATCC 25923 with lowest MIC
0.9375 mg/mL as compared to the standard drugs ciproflox-
acin (MIC 3.75 mg/mL) and gatifloxacin (MIC 1.875 mg/mL).
The newly synthesized compounds were also tested for
approximate lethal dose LD50 and were found to exhibit a
higher value of LD50 i.e. more than 800 mg/kg except com-
pound 5i which exhibited LD50 of more than 1600 mg/kg
(maximum dose tested). The compounds have shown high
value of LD50 indicating good safety margin.
H C
3
H C
3
O
O
Br
O
CH
3
dry Acetone
anh. K CO
O
O
2
3
R
R
(2a-2b)
(1a-1b)
85% Hydrazine Hydrate
EtOH
R = H, Cl
1
H
N
R
= CH
3
O
NH
2
OCH
3
H
C
O
3
Br
Cl
C H
2
5
O
R
(3a-3b)
1
R
SCN
S
1
H
N
R
N
H
O
N
H
H C
3
O
O
R
(4a-4j)
NaOH
KI/I
2
N
O
H
C
O
N
3
HN
1
R
O
R
(5a-5j)
Scheme 1. Synthetic route of oxadiazole derivatives.
compounds were based on elemental (C, H, N) and spectral (IR,
1H-NMR and MS) analysis.
Results and discussion
Conclusion
The antibacterial activity of all the newly synthesized com-
pounds (4a–4j and 5a–5j) and the standard drugs ciproflox-
acin and gatifloxacin were carried out against both types of
Gram negative bacteria (Pseudomonas aeruginosa ATCC 27853,
Klebsiella pneumoniae CIP 53153, Escherichia coli ATCC 25922)
and Gram positive bacteria (Staphylococcus aureus ATCC 25923).
Diameter of zone of inhibition in mm and minimal
1. In general oxadiazole derivatives (i.e. 5a–5j) are more
active than their parent compounds (4a–4j).
2. Compounds having a substitution with 2-chlorophenyl
ring (i.e. compound 5i) showed promising antibacterial
activity against both types of bacteria.
ß 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

468
H. Kaur et al.
Arch. Pharm. Chem. Life Sci. 2011, 344, 466–473
Table 1. Inhibitory-zone diameter (in mm) of the synthesized compounds 4a–4j and 5a–5j against the tested bacterial strains.
S
R1
H
N
N
N
H
O
N
H
O
H3C
O
H3C
O
N
HN
R1
O
O
R
R
(4a-4j)
(5a-5j)
Comp. No.
R
R’
Antibacterial activitya
Diameter of the inhibition zone (in mm)
LD50
mg/kg
Pseudomonas
aeruginosa ATCC
27853
Klebsiella
pneumoniae
CIP 53153
Escherichia
coli ATCC
25922
Staphylococcus
aureus ATCC
25923
4a
4b
4c
4d
4e
4f
4g
4h
4i
4j
5a
5b
5c
5d
5e
H
H
H
H
CH3
OCH3
Br
–
7
10
12
–
6
–
15
10
–
9
7
–
17
8
–
–
>800
>800
>800
>800
>800
>800
>800
>800
>800
>800
>800
>800
>800
>800
>800
>800
>800
>800
>1600
>800
11
13
15
12
10
12
20
–
Cl
H
C2H5
CH3
OCH3
Br
Cl
Cl
Cl
Cl
Cl
H
H
H
H
H
Cl
Cl
Cl
Cl
Cl
–
–
–
7
10
13
20
–
10
16
16
–
12
14
18
8
10
21
21
10
10
12
–
12
15
20
12
16
26
10
22
25
Cl
C2H5
CH3
OCH3
Br
–
–
10
16
20
15
–
18
21
27
7
10
13
10
15
14
12
20
28
16
25
23
Cl
C2H5
CH3
OCH3
Br
Cl
C2H5
–
6
5f
5g
5h
5i
18
20
19
28
19
21
26
5j
Ciprofloxacin
Gattifloxacin
24
22
–
–
Institute (Lucknow, India). 13C-NMR spectra were recorded on a
Bruker Avance 400 MHz spectrometer using solvent peak as
internal standard. Mass spectra were determined on a Jeol SX
102 (FAB) spectrometer. The progress of the reaction is moni-
tored by TLC and product are purified through recrystallization
and purity of the compounds was checked by thin layer chroma-
tography (TLC) performed on silica gel G coated plate of 0.5 mm
thickness.
3. All the compounds exhibited LD50 > 800 mg/kg,
except compound 5i (having 2-chlorophenyl ring)
which showed LD50 > 1600 mg/kg.
Experimental
General
Melting points were determined in open capillary tubes and are
uncorrected. Infrared (IR) spectra were recorded in KBr on Perkin-
Chemistry
General procedure for synthesis of 2-(4-(3-
substitutedbenzoyl)-2-methylphenoxy) acetates 2a–2b
Elmer-spectrum RX-I instrument and nmax was recorded in cmꢀ1
.
1H-NMR spectra were recorded on a Hitachi 300 MHz using TMS
as internal standard (chemical shifts (d) in ppm) and Elemental
analysis (C, H, N) of all the compounds were performed on CHN
analyzer, Carlo Erba 1108 analyzer at the Central Drug Research
A mixture of substituted 4-hydroxybenzophenones (1a–1b)
(2.0 mol), ethyl bromoacetate (2.0 mol) and potassium carbonate
ß 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

Arch. Pharm. Chem. Life Sci. 2011, 344, 466–473
Synthesis of New Oxadiazole Derivatives
469
Table 2. Minimal inhibitor concentration (MIC) mg/mL of synthesized compounds 4a–4j and 5a–5j against the tested bacterial strains.
S
R1
H
N
N
N
H
O
N
H
O
H3C
O
H3C
O
N
HN
R1
O
O
R
R
(4a-4j)
(5a-5j)
Pseudomonas
aeruginosa
ATCC 27853
Klebsiella
pneumoniae
CIP 53153
Escherichia
coli ATCC
25922
Staphylococcus
aureus ATCC
25923
4a
4b
4c
4d
4e
4f
4g
4h
4
4j
5a
5b
5c
5d
5e
H
H
H
H
H
Cl
Cl
Cl
Cl
Cl
H
H
H
H
H
Cl
Cl
Cl
Cl
Cl
–
CH3
OCH3
Br
–
60
150
180
–
300
–
180
130
–
–
150
30
120
–
120
15
60
60
60
30
30
15
1.875
60
Nil
3.75
3.75
150
240
180
60
120
150
150
15
15
120
60
60
–
15
60
15
15
15
3.75
15
Nil
7.5
3.75
–
–
270
120
60
90
120
30
15
–
120
90
150
30
30
15
Cl
C2H5
CH3
OCH3
Br
–
120
60
15
–
Cl
C2H5
CH3
OCH3
Br
–
30
120
15
15
–
15
7.50
3.75
30
Nil
15
7.5
Cl
C2H5
CH3
OCH3
Br
Cl
C2H5
–
5f
5g
5h
5i
30
7.50
0.9375
30
Nil
3.75
1.875
5j
Control
Ciprofloxacin
Gattifloxacin
–
–
–
–
(10 g) in dry acetone (150 mL) were refluxed for 6 h. To the
cooled reaction mixture, water (150 mL) was added and
extracted with ether. The ether layer washed with 5% aqueous
sodium hydroxide and with water and dried over anhydrous
sodium sulphate and evaporated. The crude product on recrys-
tallization from appropriate solvents yielded 2a–2b.
Ethyl-2-(4-(3-chlorobenzoyl)-2-methylphenoxy)acetate 2b
Yield 80% (acetone); m.p. 738C. IR (KBr) n 2995 (C-H aromatic),
1688 (C O), 748 (C-Cl) cmꢀ1; 1H-NMR (CDCl3) d: 7.82–6.92 (m, 7H,
–
–
J ¼ 8.7 Hz, aromatic-H), 3.70 (q, 2H, J ¼ 7 Hz, CH2CH3), 2.48
(s, 2H, CH2), 1.40 (t, 3H, J ¼ 7 Hz, CH2CH3), 2.30 (s, 3H, CH3)
ppm; 13C-NMR (CDCl3) 187.0, 171.0, 166.4, 139.2, 133.5, 132.6,
131.8, 130.5, 130.0, 129.6, 128.2, 128.1, 123.0, 113.7, 75.9, 59.5,
13.6, 11.0. MS (m/z): 332.78 [Mþ]. Anal. calcd. for C18H17ClO4:
C, 64.97; H, 5.15. Found: C, 64.90; H, 5.18%.
Ethyl-2-(4-benzoyl-2-methylphenoxy)acetate 2a
Yield 88% (methanol); m.p. 768C. IR (KBr) n 2990 (C-H aromatic),
1690 (C O) cmꢀ1; 1H-NMR (CDCl3) d: 7.86–6.90 (m, 8H, J ¼ 8.6 Hz,
–
–
aromatic-H), 3.60 (q, 2H, J ¼ 7 Hz, CH2CH3), 2.50 (s, 2H, CH2), 1.34
(t, 3H, J ¼ 7 Hz, CH2CH3), 2.32 (s, 3H, CH3) ppm. 13C-NMR (CDCl3)
187.0, 171.0, 166.4, 137.8, 132.2, 131.8, 130.1, 130.0, 128.2, 128.1,
123.0, 113.7, 75.9, 59.5, 13.6, 11.0. MS (m/z): 298.12 [Mþ].
Anal. calcd. for C18H18O4: C, 72.47; H, 6.08. Found: C, 72.49; H,
6.0.10%.
General procedure for synthesis of 2-(4-
(3-substitutedbenzoyl)-2-methylphenoxy)acetohydrazides
3a–3b
To an ethanolic solution (25 mL) of ester (1.2 mol), hydrazine
monohydrate (1.2 mol) was added and the reaction mixture was
ß 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

470
H. Kaur et al.
Arch. Pharm. Chem. Life Sci. 2011, 344, 466–473
kept aside for 2 h. The white crystalline solid separated was
filtered, washed with ethanol dried and recrystallized from
hot suitable solvents to give 3a–3b.
130.1, 130.0, 128.2, 128.1, 123.0, 125.5, 126.3, 125.0, 121.1,
114.4, 113.7, 78.9, 56.0, 11.0. MS (m/z): 449.52 [Mþ]. Anal. calcd.
for C24H23N3O4S: C, 64.13; H, 5.16; N, 9.35. Found: C, 64.17; H,
5.11; N, 9.37%.
2-(4-Benzoyl-2-methylphenoxy)acetohydrazide 3a
Yield 75% (ethanol); m.p. 1678C. IR (KBr) n 3340 (NH), 2992 (C-H
2-(2-(4-Benzoyl-2-methylphenoxy)acetyl)-N-(2-
bromophenyl)hydrazinecarbothioamide 4c
aromatic), 1686 (C O) cmꢀ1; 1H-NMR (CDCl3) d: 8.40 (brs, 1H, NH,
–
–
D2O exchangeable), 8.30 (brs, 2H, NH2, D2O exchangeable), 7.80–
6.91 (m, 8H, J ¼ 8.9 Hz, aromatic-H), 2.50 (s, 2H, CH2), 2.33 (s, 3H,
CH3) ppm; 13C-NMR (CDCl3) 187.0, 170.3, 166.4, 137.8, 132.2,
131.8, 131.0, 130.1, 130.0, 128.2, 128.1, 123.0, 121.1, 113.7,
78.3, 11.0. MS (m/z): 284.31 [Mþ]. Anal. calcd. for C16H16N2O3:
C, 67.59; H, 5.67; N, 9.85. Found: C, 67.63; H, 5.63; N, 9.86%.
Yield 74% (acetone); m.p. 2048C. IR (KBr) n 3452 (NH), 3014 (C-H
ꢀ1
–
–
aromatic), 1689 (C O), 1305 (CN), 1128 (C S), 610 (C-Br) cm
;
–
–
1H-NMR (CDCl3) d: 8.92 (brs, 1H, NH-Ar, D2O exchangeable), 8.75
–
(brs, 1H, NHC S, D O exchangeable), 8.50 (brs, 1H, CONH,
–
2
D2O exchangeable), 7.86–6.76 (m, 12H, J ¼ 8.6 Hz, aromatic-H),
2.75 (s, 2H, CH2), 2.30 (s, 3H, CH3) ppm; 13C-NMR (CDCl3) 187.0,
186.0, 170.3, 166.4, 142.7, 132.2, 132.1, 137.8, 130.0, 130.1, 131.8,
127.5, 127.8, 126.7, 128.2, 128.1, 123.0, 119.9, 113.7, 78.9, 11.0.
MS (m/z): 498.39 [Mþ]. Anal. calcd. for C23H20BrN3O3S: C, 55.43; H,
4.04; N, 8.43. Found: C, 55.49; H, 4.08; N, 8.40%.
2-(4-(3-Chlorobenzoyl)-2-methylphenoxy)acetohydrazide
3b
Yield 73% (ethanol); m.p. 1638C. IR (KBr) n 3347 (NH), 2996 (C-H
ꢀ1
–
–
aromatic), 1684 (C O), 748 (C-Cl) cm
;
1H-NMR (CDCl3) d: 8.44
2-(2-(4-Benzoyl-2-methylphenoxy)acetyl)-N-(2-
chlorophenyl)hydrazinecarbothioamide 4d
(brs, 1H, NH, D2O exchangeable), 8.28 (brs, 2H, NH2, D2O
exchangeable), 7.90–6.71 (m, 7H, J ¼ 9 Hz, aromatic-H), 2.56
(s, 2H, CH2), 2.37 (s, 3H, CH3) ppm; 13C-NMR (CDCl3) 187.0,
170.3, 166.4, 139.2, 133.5, 132.6, 131.8, 131.0, 130.5, 130.0,
129.6, 128.2, 128.1, 123.0, 113.7, 78.3, 11.0. MS (m/z): 318.75
[Mþ]. Anal. calcd. for C16H15ClN3O3: C, 60.29; H, 4.74; N, 8.79.
Found: C, 60.39; H, 4.76; N, 8.80%.
Yield 70% (methanol); m.p.1908C. IR (KBr) n 3450 (NH), 3012 (C-H
aromatic), 1682 (C O), 1302 (CN), 1132 (C S), 752 (C-Cl) cmꢀ1; 1H-
–
–
–
–
NMR (CDCl3) d: 8.90 (brs, 1H, NH-Ar, D2O exchangeable), 8.72 (brs,
–
1H, NHC S, D2O exchangeable), 8.61 (brs, 1H, CONH,
–
D2O exchangeable), 7.84–6.94 (m, 12H, J ¼ 9 Hz, aromatic-H),
2.60 (s, 2H, CH2), 2.28 (s, 3H, CH3) ppm; 13C-NMR (CDCl3)
187.0, 186.0, 170.3, 166.4, 139.8, 137.8, 132.2, 131.8, 130.6,
130.1, 130.0, 129.2, 128.2, 128.1, 126.9, 126.7, 126.7, 125.9,
123.0, 113.7, 78.9, 11.0. MS (m/z): 453.94 [Mþ]. Anal. calcd.
for C23H20ClN3O3S: C, 60.86; H, 4.44; N, 9.26. Found: C, 60.88;
H, 4.45; N, 9.20%.
General procedure for synthesis of 2-(2-(4-(3-
substitutedbenzoyl)-2-methylphenoxy)acetyl)-N-(2-
substitutedphenyl)hydrazinecarbothioamides 4a–4j
A mixture of compounds 3a–3b (0.6 mol) and substituted phenyl-
isothiocyanates (0.6 mol) in 30 mL of absolute ethanol was
refluxed for 5–6 h. After completion of the reaction, the reaction
mixture was concentrated and kept overnight at room tempera-
ture. The needle shaped crystals thus obtained were purified by
repeated washing with appropriate solvents to obtain com-
pounds 4a–4j.
2-(2-(4-Benzoyl-2-methylphenoxy)acetyl)-N-(2-
ethylphenyl)hydrazinecarbothioamides 4e
Yield 68% (methanol); m.p. 2008C. IR (KBr) n 3455 (NH), 3009 (C-H
ꢀ1
aromatic), 1684 (C O), 1304 (CN), 1130 (C S) cm
;
1H-NMR
–
–
–
–
(CDCl3) d: 8.87 (brs, 1H, NH-Ar, D2O exchangeable), 8.62 (brs,
–
1H, NHC S, D2O exchangeable), 8.50 (brs, 1H, CONH,
–
2-(2-(4-Benzoyl-2-methylphenoxy)acetyl)-N-(2-
methylphenyl)hydrazinecarbothioamide 4a
D2O exchangeable), 7.83–6.74 (m, 12H, J ¼ 9 Hz, aromatic-H),
3.02 (q, 2H, J ¼ 6.5 Hz, CH2CH3), 2.66 (s, 2H, CH2), 2.30 (s, 3H,
CH3), 1.20 (t, 3H, J ¼ 6.6 Hz, CH2CH3) ppm; 13C-NMR (CDCl3)
194.3, 166.3, 181.1, 162.3, 138.4, 135.8, 134.6, 132.4, 131.9,
131.5, 130.3, 128.4, 128.3, 128.2, 126.2, 124.9, 124.2, 128.4,
119.5, 113.9, 15.4, 67.2, 23.7, 14.5. MS (m/z): 447.55 [Mþ]. Anal.
calcd. for C25H25N3O3S: C, 67.09; H, 5.63; N, 9.39. Found: C, 67.03;
H, 5.62; N, 9.45%.
Yield 78% (ethanol); m.p. 1878C. IR (KBr) n 3450 (NHꢀ),13010 (C-H
aromatic), 1682 (C O), 1304 (CN), 1129 (C S) cm
;
1H-NMR
–
–
–
–
(CDCl3) d: 8.90 (brs, 1H, NH-Ar, D2O exchangeable), 8.75 (brs,
–
1H, NHC S, D O exchangeable), 8.60 (brs, 1H, CONH, D O
–
2
2
exchangeable), 7.80–6.91 (m, 12H, J ¼ 8.6 Hz, aromatic-H), 2.70
(s, 2H, CH2), 2.35 (s, 6H, 2 ꢁ CH3) ppm; 13C-NMR (CDCl3) 187.0,
170.3, 186.0, 166.4, 140.1, 137.8, 134.5, 132.2, 131.8, 130.1, 130.0,
129.5, 128.2, 125.8, 125.2, 124.4, 123.0, 113.7, 78.9, 12.4, 11.0. MS
(m/z): 433.52 [Mþ]. Anal. calcd. for C24H23N3O3S: C, 66.49; H, 5.35;
N, 9.69. Found: C, 66.43; H, 5.34; N, 9.72%.
2-(2-(4-(3-Chlorobenzoyl)-2-methylphenoxy)acetyl)-N-(2-
methylphenyl)hydrazinecarbothioamide 4f
Yield 72% (DMF); m.p. 1798C. IR (KBr) n 3448 (NH), 3013 (C-H
aromatic), 1686 (C O), 1306 (CN), 1129 (C S), 744 (C-Cl) cmꢀ1; 1H-
–
–
–
–
2-(2-(4-Benzoyl-2-methylphenoxy)acetyl)-N-(2-
methoxyphenyl)hydrazinecarbothioamide 4b
NMR (CDCl3) d: 8.93 (brs, 1H, NH-Ar, D2O exchangeable), 8.70 (brs,
–
1H, NHC S, D2O exchangeable), 8.60 (brs, 1H, CONH,
–
Yield 75% (methanol); m.p. 1988C. IR (KBr) n 3450 (NH), 3008 (C-H
D2O exchangeable), 7.84–6.94 (m, 11H, J ¼ 8.7 Hz, aromatic-H),
2.63 (s, 2H, CH2), 2.35 (s, 6H, 2 ꢁ CH3) ppm; 13C-NMR (CDCl3)
187.0, 166.0, 186.0, 170.3, 140.1, 139.2, 134.5, 133.5, 132.6,
131.8, 130.0, 129.6, 128.2, 125.8, 125.2, 124.4, 113.7, 78.9,
12.4, 11.0. MS (m/z): 467.97 [Mþ]. Anal. calcd. for
C24H22ClN3O3S: C, 61.60; H, 4.74; N, 8.98. Found: C, 61.69; H,
4.78; N, 8.92%.
ꢀ1
;
1H-NMR
–
–
aromatic), 1687 (C O), 1310 (CN), 1130 (C S) cm
–
–
(CDCl3) d: 8.94 (brs, 1H, NH-Ar, D2O exchangeable), 8.75 (brs,
–
1H, NHC S, D O exchangeable), 8.60 (brs, 1H, CONH, D O
–
2
2
exchangeable), 7.80–6.91 (m, 12H, J ¼ 9 Hz, aromatic-H), 3.56
(s, 3H, OCH3), 2.72 (s, 2H, CH2), 2.32 (s, 3H, CH3) ppm; 13C-NMR
(CDCl3) 187.0, 186.0, 170.3, 166.4, 158.8, 137.8, 132.2, 131.8,
ß 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

Arch. Pharm. Chem. Life Sci. 2011, 344, 466–473
Synthesis of New Oxadiazole Derivatives
471
was cooled under continuous stirring for 30 min. To this mix-
ture, iodine in KI (5%) was added dropwise till the color of iodine
persisted at room temperature. After that the mixture was
refluxed for 2h. After completion of the reaction, the reaction
mixture was poured onto crushed ice. The solid thus obtained
was washed with sodium thiosulphate solution and recrystal-
lized from suitable solvents to yielded compounds 5a–5j.
2-(2-(4-(3-Chlorobenzoyl)-2-methylphenoxy)acetyl)-N-(2-
methoxyphenyl)hydrazinecarbothioamide 4g
Yield 75% (ethanol); m.p. 1898C. IR (KBr) n 3443 (NH), 3010 (C-H
ꢀ1
–
–
aromatic), 1690 (C O), 1302 (CN), 1131 (C S), 751 (C-Cl) cm
;
–
–
1H-NMR (CDCl3) d: 8.83 (brs, 1H, NH-Ar, D2O exchangeable), 8.73
(brs, 1H, NHC S, D O exchangeable), 8.62 (brs, 1H, CONH,
–
–
2
D2O exchangeable), 7.89–6.84 (m, 11H, J ¼ 9 Hz, aromatic-H),
3.58 (s, 3H, OCH3), 2.67 (s, 2H, CH2), 2.38 (s, 3H, CH3) ppm;
13C-NMR (CDCl3) 187.0, 186.0, 170.3, 166.4, 158.8, 139.2, 133.5,
132.6, 131.8, 130.5, 130.0, 129.6, 128.2, 128.1, 126.3, 125.5, 125.0,
123.0, 121.1, 114.4, 78.9, 11.0. MS (m/z): 483.97 [Mþ]. Anal. calcd.
for C24H22ClN3O4S: C, 59.56; H, 4.58; N, 8.68. Found: C, 59.59; H,
4.50; N, 8.67%.
(3-Methyl-4-((5-(3-methylphenyl)-1,3,4-oxadiazol-2-yl)
methoxy)phenyl)phenyl)methanone 5
Yield 71% (methanol); m.p. 2308C. IR (KBr) n 3442 (NH), 2972 (C-H
ꢀ1
–
–
aromatic), 1712 (C O), 1312 (CN), 1004 (C-O-C) cm
;
1H-NMR
(CDCl3) d: 10.60 (brs, 1H, NH, D2O exchangeable), 7.89–6.70 (m,
12H, J ¼ 9 Hz, aromatic-H), 3.24 (s, 2H, CH2), 3.10 (s, 6H, 2 ꢁ CH3)
ppm; 13C-NMR (CDCl3) 187.0, 166.4, 147.4, 137.8, 132.2, 131.8,
130.1, 130.0, 128.2, 128.1, 128.0, 126.3, 124.3, 123.0, 118.4, 115.0,
72.3, 12.1, 11.0. MS (m/z): 399.44 [Mþ]. Anal. calcd. for C24H21N3O3:
C, 72.16; H, 5.30; N, 10.52. Found: C, 72.19; H, 5.28; N, 10.58%.
N-(2-Bromophenyl)-2-(2-(4-(3-chlorobenzoyl)-2-
methylphenoxy)acetyl)hydrazinecarbothioamide 4h
Yield 73% (methanol); m.p. 2098C. IR (KBr) n 3460 (NH), 3012 (C-H
–
–
aromatic), 1685 (C O), 1306 (CN), 1134 (C S), 748 (C-Cl), 614 (C-Br)
1
–
–
cmꢀ1; H-NMR (CDCl3) d: 8.88 (brs, 1H, NH-Ar, D2O exchangeable),
–
(4-((5-(2-Methoxyphenylamino)-1,3,4-oxadiazol-2-yl)
methoxy)-3-methylphenyl)phenyl)methanone 5b
8.69 (brs, 1H, NHC S, D O exchangeable), 8.61 (brs, 1H, CONH, D O
–
2
2
exchangeable), 7.78–6.92 (m, 11H, J ¼ 8.8 Hz, aromatic-H), 2.62
(s, 2H, CH2), 2.32 (s, 3H, CH3) ppm; 13C-NMR (CDCl3) 194.3, 181.1,
166.3, 162.3, 141.1, 138.3, 137.2, 132.5, 132.2, 131.9, 131.5, 131.4,
130.5, 129.8, 128.4, 128.3, 128.0, 124.4, 124.2, 113.9, 67.2, 15.4. MS
(m/z): 532.84 [Mþ]. Anal. calcd. for C23H19BrClN3O3S: C, 51.84; H, 3.59;
N, 7.89. Found: C, 51.88; H, 3.63; N, 7.84%.
Yield 75% (acetone); m.p. 2368C. IR (KBr) n 3448 (NHꢀ),12980 (C-H
–
–
aromatic), 1710 (C O), 1314 (CN), 1009 (C-O-C) cm
;
1H-NMR
(CDCl3) d: 10.50 (brs, 1H, NH, D2O exchangeable), 7.86–6.74 (m,
12H, J ¼ 8.6 Hz, aromatic-H), 3.60 (s, 3H, OCH3), 3.26 (s, 2H, CH2),
3.15 (s, 3H, CH3) ppm; 13C-NMR (CDCl3) 187.0, 166.4, 148.6, 137.8,
132.3, 132.2, 131.8, 130.1, 131.0, 130.0, 128.2, 128.1, 123.0, 121.6,
119.5, 116.1, 114.9, 113.7, 72.3, 56.0. MS (m/z): 415.44 [Mþ]. Anal.
calcd. for C24H21N3O4: C, 69.39; H, 5.10; N, 10.11. Found: C, 69.45;
H, 5.12; N, 10.18%.
2-(2-(4-(3-Chlorobenzoyl)-2-methylphenoxy)acetyl)-N-
(2-chlorophenyl)hydrazinecarbothioamide 4i
Yield 70% (ethanol); m.p. 2108C. IR (KBr) n 3447 (NH), 3013 (C-H
ꢀ1
–
–
aromatic), 1690 (C O), 1302 (CN), 1130 (C S), 754 (C-Cl) cm
;
–
–
1H-NMR (CDCl3) d: 8.97 (brs, 1H, NH-Ar, D2O exchangeable), 8.76
(brs, 1H, NHC S, D O exchangeable), 8.66 (brs, 1H, CONH,
(4-((5-(2-Bromophenylamino)-1,3,4-oxadiazol-2-yl)
methoxy)-3-methylphenyl)phenyl)methanone 5c
–
–
2
D2O exchangeable), 7.74–6.84 (m, 11H, J ¼ 9 Hz, aromatic-H), 2.61
(s, 2H, CH2), 2.35 (s, 3H, CH3) ppm; 13C-NMR (CDCl3) 194.3, 181.1,
166.3, 162.3, 141.1, 138.3, 135.9, 133.9, 132.5, 131.9, 131.5, 130.2,
131.4, 130.5, 129.8, 128.4, 128.3, 124.4, 124.3, 124.2, 113.9, 67.2, 15.4,
13.4. MS (m/z): 488.39 [Mþ]. Anal. calcd. for C23H19Cl2N3O3S: C, 56.56;
H, 3.92; N, 8.60. Found: C, 56.60; H, 3.90; N, 8.67%.
Yield 75% (acetone); m.p. 2508C. IR (KBr) n 3455 (NH), 2970 (C-H
ꢀ1
–
aromatic), 1710 (C O), 1314 (CN), 1012 (C-O-C), 612 (C-Br) cm
;
–
1H-NMR (CDCl3) d: 10.20 (brs, 1H, NH, D2O exchangeable), 7.89–
6.70 (m, 12H, J ¼ 8.7 Hz, aromatic-H), 3.28 (s, 2H, CH2), 3.17 (s,
3H, CH3) ppm; 13C-NMR (CDCl3) 187.0, 166.4, 160.0, 150.0, 137.8,
132.6, 131.8, 130.1, 130.0, 128.3, 128.2, 128.1, 123.0, 120.7, 117.3,
113.7, 109.7, 72.3, 32.2, 28.2, 11.0. MS (m/z): 464.31 [Mþ]. Anal.
calcd. for C23H18BrN3O3: C, 59.50; H, 3.91; N, 9.05. Found: C,
59.47; H, 3.95; N, 9.02%.
2-(2-(4-(3-Chlorobenzoyl)-2-methylphenoxy)acetyl)-N-
(2-ethylphenyl)hydrazinecarbothioamide 4j
Yield 70% (methanol); m.p. 1968C. IR (KBr) n 3457 (NH), 3015 (C-H
1
aromatic), 1686 (C O), 1300 (CN), 1127 (C S), 749 (C-Cl) cmꢀ1; H-
–
–
(4-((5-(2-Chlorophenylamino)-1,3,4-oxadiazol-2-yl)
methoxy)-3-methylphenyl)phenyl)methanone 5d
–
–
NMR (CDCl3) d: 8.93 (brs, 1H, NH-Ar, D2O exchangeable), 8.70 (brs, 1H,
–
NHC S, D O exchangeable), 8.60 (brs, 1H, CONH, D O exchangeable),
–
2
2
Yield 74% (methanol); m.p. 2468C. IR (KBr) n 3448 (NH), 2982 (C-H
ꢀ1
7.87–6.90 (m, 11H, J ¼ 9 Hz, aromatic-H), 3.05 (q, 2H,
J ¼ 6.6 Hz, CH2CH3), 2.60 (s, 2H, CH2), 2.34 (s, 3H, CH3), 1.25 (t,
3H, J ¼ 6.6 Hz, CH2CH3) ppm; 13C-NMR (CDCl3) 194.3, 181.1, 166.3,
162.3, 141.1, 135.8, 134.6, 132.5, 131.5, 131.4, 131.3, 130.3, 129.8,
128.4, 128.3, 128.2, 126.2, 124.9, 124.2, 119.5, 113.9, 109.8, 67.2, 23.7,
15.4, 14.5. MS (m/z): 481.99 [Mþ]. Anal. calcd. for C25H24ClN3O3S: C,
62.30; H, 5.02; N, 8.72. Found: C, 62.32; H, 5.00; N, 8.75%.
–
aromatic), 1720 (C O), 1308 (CN), 1008 (C-O-C), 756 (C-Cl) cm
;
–
1H-NMR (CDCl3) d: 10.30 (brs, 1H, NH, D2O exchangeable), 7.99–
6.80 (m, 12H, J ¼ 9 Hz, aromatic-H), 3.25 (s, 2H, CH2), 3.17 (s, 3H,
CH3) ppm; 13C-NMR (CDCl3) 187.0, 166.4, 147.1, 137.8, 131.8,
132.2, 130.1, 130.0, 129.7, 128.2, 128.1, 127.4, 123.0, 120.4,
119.9, 116.5, 113.7, 72.3, 11.0. MS (m/z): 419.86 [Mþ]. Anal. calcd.
for C23H18ClN3O3: C, 65.79; H, 4.32; N, 10.01. Found: C, 65.71; H,
4.30; N, 10.07%.
General procedure for synthesis of (3-substitutedphenyl)-
(3-methyl-4-((5-(2-substitutedphenylamino)-1,3,4-
oxadiazol-2-yl)methoxy)phenyl)methanones 5a–5j
(4-((5-(2-Ethylphenylamino)-1,3,4-oxadiazol-2-yl)
methoxy)-3-methylphenyl)phenyl)methanone 5e
Yield 72% (ethanol); m.p. 2618C. IR (KBr) n 3455 (NHꢀ),12982 (C-H
A solution of substituted hydrazinecarbothioamides 4a–4j
(0.07 mol) and sodium hydroxide (10 mL) in 50 mL of ethanol
1H-NMR
–
–
aromatic), 1718 (C O), 1310 (CN), 1010 (C-O-C) cm
;
ß 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

472
H. Kaur et al.
Arch. Pharm. Chem. Life Sci. 2011, 344, 466–473
(CDCl3) d: 10.33 (brs, 1H, NH, D2O exchangeable), 7.70–6.78 (m, 12H,
J ¼ 8.7 Hz, aromatic-H), 3.45 (q, 2H, J ¼ 6.6 Hz, CH2CH3), 3.29 (s, 2H,
CH2), 3.20 (s, 3H, CH3), 1.25 (t, 3H, J ¼ 6.5 Hz, CH2CH3) ppm; 13C-
NMR (CDCl3) 187.0, 166.4, 146.1, 137.8, 132.2, 131.8, 130.0, 130.1,
128.7, 128.2, 128.1, 126.5, 126.8, 123.0, 118.4, 115.0, 113.7, 72.3,
19.8, 16.1, 11.0. MS (m/z): 413.47 [Mþ]. Anal. calcd. for C25H23N3O3: C,
72.62; H, 5.61; N, 10.16. Found: C, 72.66; H, 5.67; N, 10.0%.
1H-NMR (CDCl3) d: 10.62 (brs, 1H, NH, D2O exchangeable), 7.89–
6.60 (m, 11H, J ¼ 8.8 Hz, aromatic-H), 3.45 (q, 2H,
J ¼ 6.5 Hz, CH2CH3), 3.24 (s, 2H, CH2), 3.19 (s, 3H, CH3), 1.35 (t,
3H, J ¼ 6.5 Hz, CH2CH3) ppm; 13C-NMR (CDCl3) 187.0, 166.4,
146.1, 139.2, 133.5, 132.6, 131.8, 130.5, 130.0, 129.6, 128.7,
128.2, 128.1, 126.8, 126.5, 123.0, 118.4, 113.7, 115.0, 72.3,
19.8, 16.1, 11.0. MS (m/z): 447.91 [Mþ]. Anal. calcd.
for C25H22ClN3O3: C, 67.04; H, 4.95; N, 9.38. Found: C, 67.09;
H, 4.99; N, 9.30%.
(3-Chlorophenyl)(3-methyl-4-((5-(2-methylphenylamino)-
1,3,4-oxadiazol-2-yl)methoxy) phenyl) methanone 5f
Yield 70% (methanol); m.p. 2158C. IR (KBr) n 3454 (NH), 2986 (C-H
Biological studies
Antibacterial activity
ꢀ1
–
aromatic), 1712 (C O), 1304 (CN), 1014 (C-O-C), 752 (C-Cl) cm
;
–
1H-NMR (DMSO-d6) d: 10.24 (brs, 1H, NH, D2O exchangeable),
7.86–6.78 (m, 11H, J ¼ 9 Hz, aromatic-H), 3.23 (s, 2H, CH2),
3.17 (s, 6H, 2 ꢁ CH3) ppm; 13C-NMR (CDCl3) 187.0, 166.4,
147.4, 139.2, 133.5, 132.6, 131.3, 130.5, 130.0, 129.6, 128.2,
128.1, 126.3, 124.3, 123.0, 118.4, 115.0, 113.7, 72.3, 12.1, 11.0.
MS (m/z): 433.89 [Mþ]. Anal. calcd. for C24H20ClN3O3: C, 66.44; H,
4.65; N, 9.68. Found: C, 66.49; H, 4.69; N, 9.66%.
The newly synthesized compounds 4a–4j and 5a–5j were
screened for antibacterial activity against bacterial strains
namely Pseudomonas aeruginosa ATCC 27853, Klebsiella pneumoniae
CIP 53153, Escherichia coli ATCC 25922, and Staphylococcus aureus
ATCC 25923 at a concentration of 300 mg/mL by the filter paper
disc-method [10]. For comparison, ciprofloxacin and gattiflox-
acin were used as the standard drugs. DMSO served as control
and there was no visible change in bacterial growth due to this.
The discs of Whatman filter paper were prepared with standard
size (7 mm) and kept into one-Oz screw-capped wide-mouthed
containers for sterilization. These bottles are kept in the hot-air
oven at 1508C. Now, solution is put into each bottle. The discs are
transferred to the inoculated plates with a pair of fine pointed
tweezers. To prevent contamination, tweezers may be kept with
their tips in 70% alcohol and flamed off before use. Before using
the test organisms, grown on nutrient agar, they were subcul-
tured on nutrient broth at 378C for 18–20 h. Each disc was
carefully applied to the surface of the agar without lateral move-
ment once the surface had been touched. Now, the plates incu-
bated for 24 h at 378C.
(3-Chlorophenyl)(4-((5-(2-methoxyphenylamino)-1,3,4-
oxadiazol-2-yl)methoxy)-3-methylphenyl) methanone 5g
Yield 69% (methanol); m.p. 2428C. IR (KBr) n 3448 (NH), 2990 (C-H
ꢀ1
–
aromatic), 1730 (C O), 1312 (CN), 1008 (C-O-C), 749 (C-Cl) cm
;
–
1H-NMR (CDCl3) d: 10.50 (brs, 1H, NH, D2O exchangeable), 7.80–
6.77 (m, 11H, J ¼ 9 Hz, aromatic-H), 3.66 (s, 3H, OCH3), 3.22 (s, 2H,
CH2), 3.16 (s, 3H, CH3) ppm; 13C-NMR (CDCl3) 187.0, 166.4, 148.6,
139.2, 132.6, 133.5, 132.3, 131.8, 130.5, 130.0, 129.6, 128.2, 128.1,
123.0, 121.6, 119.5, 116.1, 114.9, 113.7, 72.0, 56.0, 11.0. MS (m/z):
449.89 [Mþ]. Anal. calcd. for C24H20ClN3O4: C, 64.07; H, 4.48; N,
9.34. Found: C, 64.00; H, 4.46; N, 9.39%.
(4-((5-(2-Bromophenylamino)-1,3,4-oxadiazol-2-yl)
methoxy)-3-methylphenyl)(3-chlorophenyl) methanone 5h
Yield 70% (acetone); m.p. 2548C. IR (KBr) n 3450 (NH), 2995 (C-H
Minimal inhibitory concentration (MIC)
The antibacterial activity was assayed in vitro by two-fold broth
dilution [11] against the bacterial strains Pseudomonas aeruginosa
ATCC 27853, Klebsiella pneumoniae CIP 53153, Escherichia coli ATCC
25922, and Staphylococcus aureus ATCC 25923. The minimal inhibi-
tory concentrations (MIC, in mg/mL) were defined as the lowest
concentrations of compound that completely inhibited the
growth of each strain. All compounds dissolved in dimethylsulf-
oxide were added to the culture media. Mueller-Hinton Broth for
bacteria was used to obtain the final concentrations ranging
from 300 to 0.9375 mg/mL. The amounts of dimethylsulfoxide
never exceed 1% v/v. Inocula consisted of 5.0 ꢁ 104 bacteria/mL.
The MICs were read after incubation at 378C for 24 h. (bacteria).
Media and media with 1% v/v dimethylsulfoxide were employed
as growth controls. Ciprofloxacin and gattifloxacin were used as
reference antibacterial activity, subcutaneous were performed
by transferring 100 mL of each mixture remaining clear in 1 mL
of fresh medium. The minimal bactericidal concentrations (MBC,
mg/mL) were read after incubation at 378C for 48 h.
–
aromatic), 1722 (C O), 1310 (CN), 1006 (C-O-C), 749 (C-Cl), 614 (C-
–
Br) cmꢀ1 1H-NMR (CDCl3) d: 10.54 (brs, 1H, NH, D2O exchange-
;
able), 7.69–6.70 (m, 11H, J ¼ 9.1 Hz, aromatic-H), 3.20 (s, 2H,
CH2), 3.13 (s, 3H, CH3) ppm; 13C-NMR (CDCl3) 187.0, 166.4,
150.0, 139.2, 133.5, 132.6, 131.8, 130.5, 130.0, 129.6, 128.3,
128.2, 128.1, 123.0, 120.7, 109.7, 113.7, 72.3, 11.0. MS (m/z):
498.76 [Mþ]. Anal. calcd. for C23H17BrClN3O3: C, 55.39; H, 3.44;
N, 8.42. Found: C, 55.42; H, 3.48; N, 8.40%.
(3-Chlorophenyl)(4-((5-(2-chlorophenylamino)-1,3,4-
oxadiazol-2-yl)methoxy)-3-methylphenyl) methanone 5i
Yield 72% (ethanol); m.p. 2488C. IR (KBr) n 3448 (NH), 2990 (C-H
aromatic), 1730 (C O), 1312 (CN), 1008 (C-O-C), 759 (C-Cl) cmꢀ1; 1H-
–
–
NMR (CDCl3) d: 10.57 (brs, 1H, NH, D2O exchangeable), 7.9–6.80 (m,
11H, J ¼ 9 Hz, aromatic-H), 3.27 (s, 2H, CH2), 3.16 (s, 3H, CH3) ppm;
13C-NMR (CDCl3) 187.0, 166.4, 147.1, 139.2, 133.5, 132.6, 131.8, 130.5,
130.0, 129.7, 129.6, 128.2, 128.1, 127.4, 123.0, 120.4, 119.9, 116.5,
113.7, 72.3, 11.0. MS (m/z): 454.31 [Mþ]. Anal. calcd. for C23H17Cl2N3O3:
C, 60.81; H, 3.77; N, 9.25. Found: C, 60.88; H, 3.70; N, 9.23%.
Approximate lethal dose (LD50
)
The compounds were investigated for this acute toxicity (LD50) in
albino mice by following the method of Q. E. Smith [12]. Test
compounds were administered orally in one group and the same
volume of normal saline in another group of animals consisting
six mice each in graded doses. During the study, the animals
were allowed to take water and food ad libidum. After 24 h of
(3-Chlorophenyl)(4-((5-(2-ethylphenylamino)-1,3,4-
oxadiazol-2-yl)methoxy)-3-methylphenyl) methanone 5j
Yield 73% (methanol); m.p. 2388C. IR (KBr) n 3454 (NH), 2988 (C-H
ꢀ1
–
aromatic), 1735 (C O), 1311 (CN), 1013 (C-O-C), 756 (C-Cl) cm
;
–
ß 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

Arch. Pharm. Chem. Life Sci. 2011, 344, 466–473
Synthesis of New Oxadiazole Derivatives
473
drug administration percent mortality in each group was
observed. From the data obtained LD50 was calculated.
[4] A. A. Kadi, N. R. El-Brollosy, O. A. Al-Deep, E. E. Habib, T. M.
Ibrahim, A. A. El-Emam, Eur. J. Med. Chem. 2007, 42 (2), 235–
242.
[5] H. Kumar, V. Patel, P. S. Fernandes, J. Indian Chem. Soc. 1990,
67, 401–403.
We are thankful to SAIF Punjab University, Chandigarh CDRI Lucknow,
India for spectral and analytical analysis of newly synthesized compounds.
One of the author, Hemlata Kaur is also thankful to UGC New Delhi, India,
for the award of J.RF.-Rajiv Gandhi National Junior Research Fellowship
and financial support for this work.
[6] P. V. Frank, K. S. Girish, B. Kalluraya, J. Chem. Sci. 2007, 119 (9),
41–46.
[7] S. V. Bhandari, G. B. Kailash, M. K. Raut, A. A. Patil, A. P.
Sarkate, V. J. Mokale, Bioorg. Med. Chem. 2008, 16 (4), 1822–
1831.
The authors have declared no conflict of interest.
[8] H. Kaur, S. Kumar, A. Kumar, Int. J. Chem. Technol. Res. 2010, 2
(2), 1010–1019.
[9] M. A. Omaima, M. A. E. El-Metwalli, Arch. Pharm. 2006, 325,
603–608.
References
[10] J. C. Gould, J. H. Bowie, Edinb. Med. J. 1952, 59, 178–199.
[1] V. V. Mulwad, A. C. Chaskar, Indian J. Chem. 2005, 45B, 1710–
1715.
[11] J. H. Jorgersen, J. D. Turnidge, J. A. Washington, in Manual of
Clinical Microbiology (Eds.: P. R. Murray, E. J. Baron, M. A.
Pfaller, F. C. Tenover, R. H. Nolken), American Society for
Microbiology, Washington, DC 1999, pp. 1275–1434.
[2] A. O. Maslat, M. Abussaud, H. Tashtoush, M. Al-Talib, Pol. J.
Pharmacol. 2002, 54 (1), 55–59.
[12] Q. E. Smith, Pharmacological screening tests progress in medicinal
chemistry, Vol. 1, Butterworth, London 1960, pp. 1–33.
[3] M. S. Y. Khan, C. Gita, M. Asad, M. Mueed, Indian J. Chem. 2004,
43B, 1302–1305.
ß 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com